Quarterly Cash Flow Report
Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations
Read More
We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.
First-in-class therapies to treat neurodegenerative disease
Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, PBT434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
News
Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully comple
Read More
Alterity Therapeutics talks to Finance News Network
Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drug
Read More
Alterity Therapeutics’ Finance News Network Presentation
On June 6 2019, Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, participated in the Finance News Network Inv
Read MoreReceive news from Alterity Therapeutics
